Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

September 18, 2025

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.

August 19, 2025

JAVELIN Bladder Medley data show PFS improvement with avelumab plus sacituzumab govitecan as first-line maintenance vs avelumab alone in urothelial cancer.

July 25, 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

July 24, 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

July 10, 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

June 26, 2025

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, detail the continued interest in RAS inhibition for pancreatic ductal adenocarcinoma.

May 16, 2025

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

May 09, 2025

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

April 30, 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

April 23, 2025

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.

March 30, 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

March 24, 2025

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

March 04, 2025

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

February 02, 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

February 02, 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

January 15, 2025

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

January 14, 2025

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

December 10, 2024

Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.

November 22, 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

November 06, 2024

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.